March 2025
1. OKAMURA T, Ito A, Iwaya Y, Nagaya T, et al
   Long-term evaluation of Helicobacter pylori screening in school health checkups: an 11-year study in Japan.
   J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02236.
   

   >> Share

   
   January 2025
2. LI G, Togo R, Mabe K, Nishida S, et al
   Multistage deep learning for classification of Helicobacter pylori infection status using endoscopic images.
   J Gastroenterol. 2025 Jan 15. doi: 10.1007/s00535-024-02209.
   

   >> Share

   
   March 2024
3. KURIBAYASHI S, Nakamura F, Motegi SI, Hara K, et al
   Prevalence and risk factors for medication-refractory reflux esophagitis in patients with systemic sclerosis in Japan.
   J Gastroenterol. 2024;59:179-186.
   

   >> Share

   
   February 2024
4. HUANG Y, Lu H
   Reply to: Minocycline versus tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
   J Gastroenterol. 2024 Feb 14. doi: 10.1007/s00535-024-02085.
   

   >> Share

   
   January 2024
5. LEECH T, Peiris M
   Mucosal neuroimmune mechanisms in gastro-oesophageal reflux disease (GORD) pathogenesis.
   J Gastroenterol. 2024 Jan 14. doi: 10.1007/s00535-023-02065.
   

   >> Share

   
   December 2023
6. ICHITA C, Goto T, Shimizu S
   Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
   J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
   

   >> Share

   
   
7. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
   Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
   J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
   

   >> Share

   
   November 2023
8. KAWAGUCHI T, Okamoto K, Fujimoto S, Bando M, et al
   Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway.
   J Gastroenterol. 2023 Nov 22. doi: 10.1007/s00535-023-02052.
   

   >> Share

   
   October 2023
9. KOTANI S, Shibagaki K, Hirahara N, Hasegawa N, et al
   Clinicopathologic differences of gastric neoplasms between Helicobacter pylori-infected and -naive patients: a multicenter retrospective analysis.
   J Gastroenterol. 2023 Oct 19. doi: 10.1007/s00535-023-02050.
   

   >> Share

   
   
10. HAN YY, Zhou L, Hu YL, Ding XW, et al
    Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
    J Gastroenterol. 2023 Oct 1. doi: 10.1007/s00535-023-02042.
    

    >> Share

    
    July 2023
11. WATANABE K, Iijima K
    Risk of pneumonia associated with proton pump inhibitor use.
    J Gastroenterol. 2023 Jul 16. doi: 10.1007/s00535-023-02022.
    

    >> Share

    
    June 2023
12. HIRAI R, Hirai M, Otsuka M, Mitsuhashi T, et al
    Endoscopic evaluation by the Kyoto classification of gastritis combined with serum anti-Helicobacter pylori antibody testing reliably risk-stratifies subjects in a population-based gastric cancer screening program.
    J Gastroenterol. 2023 Jun 21. doi: 10.1007/s00535-023-02010.
    

    >> Share

    
    
13. MARET-OUDA J, Panula J, Santoni G, Xie S, et al
    Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study.
    J Gastroenterol. 2023 Jun 14. doi: 10.1007/s00535-023-02007.
    

    >> Share

    
    May 2023
14. UENO M, Fujiwara T, Tokumasu H, Mano T, et al
    Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan.
    J Gastroenterol. 2023 May 12. doi: 10.1007/s00535-023-02000.
    

    >> Share

    
    April 2023
15. HUANG Y, Chen J, Ding Z, Chen X, et al
    Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
    J Gastroenterol. 2023 Apr 12. doi: 10.1007/s00535-023-01991.
    

    >> Share

    
    
16. KATO M, Hosoe N, Gotoda T, Kusano C, et al
    Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.
    J Gastroenterol. 2023;58:358-366.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share